

PANORAMIC DATA

Maximize use cases across your oncology portfolio with a comprehensive, disease-specific solution

The oncology treatment landscape is rapidly evolving, which impacts the research questions that are relevant across your portfolio at any given time. Flatiron can power more studies than ever before with Panoramic data, our largest available, non-sampled patient cohorts with real-world data across disease settings for every applicable patient in the Flatiron network.

KEY BENEFITS OF PANORAMIC DATA



Longitudinal data unlocks variables critical for research across the oncology patient journey



Biomarker data available at scale for emerging and standard of care biomarkers



Maximum non-sampled cohort sizes enable easily linked solutions and power analyses for targeted populations across assets



Comprehensive outcomes variables enable endpoint analyses across disease settings

CASE STUDY

Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting

CONTEXT

Since 2015, three CDK4/6 inhibitor (CDK4/6i) therapies — palbociclib, ribociclib, and abemaciclib — have been approved for treatment in combination with endocrine therapy, becoming the standard of care for first line treatment of HR+/HER2- metastatic breast cancer (mBC).


APPROACH

In the absence of RCTs to directly compare the effectiveness of the three CDK4/6i therapies, this study used the Flatiron Health EHR-derived Panoramic database comprised of >750,000 patients with breast cancer to compare overall survival of palbociclib, ribociclib, and abemaciclib, in combination with an aromatase inhibitor (AI) in routine US clinical practice.

IMPACT

This study is the largest real-world comparative analysis of overall survival between the CDK4/6 inhibitors in combination with an AI conducted to date. Using novel real-world data solutions, this research provides evidence that improves our understanding of treatment options for patients with mBC. Flatiron's Panoramic data offers a scaled, longitudinal, disease-specific solution that unlocks critical insights to improve care and outcomes for people with cancer.

Overall survival after sIPTW among the 3 CDK4/6 inhibitors



ABE, abemaciclib; AI, aromatase inhibitor; CDK4/6, cyclin-dependent kinase 4/6; CI, confidence interval; HR, hazard ratio; NE, not estimable; NR, not reached; OS, overall survival; PAL, palbociclib; RIB, ribociclib; sIPTW, stabilized inverse probability treatment weighting.

Rugo H, Layman R, Lynce F, et al.
 Comparative overall survival of CDK4/6is plus an aromatase inhibitor in HR+/HER2- mBC in the US real-world setting. Presented at San Antonio Breast Cancer Symposium; December 10-13; San Antonio, TX, USA. 2024.